CN116322639A - 肿瘤分类和反应性预测 - Google Patents

肿瘤分类和反应性预测 Download PDF

Info

Publication number
CN116322639A
CN116322639A CN202180066703.2A CN202180066703A CN116322639A CN 116322639 A CN116322639 A CN 116322639A CN 202180066703 A CN202180066703 A CN 202180066703A CN 116322639 A CN116322639 A CN 116322639A
Authority
CN
China
Prior art keywords
therapy
group
gene
subtype
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180066703.2A
Other languages
English (en)
Chinese (zh)
Inventor
R·S·塞茨
D·豪特
T·J·尼尔森
B·L·施魏策尔
B·Z·林
D·T·罗斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Insight Molecular Diagnostics Inc
Original Assignee
Oncocyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncocyte Corp filed Critical Oncocyte Corp
Publication of CN116322639A publication Critical patent/CN116322639A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Medical Informatics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
CN202180066703.2A 2020-08-03 2021-08-02 肿瘤分类和反应性预测 Pending CN116322639A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063060321P 2020-08-03 2020-08-03
US63/060,321 2020-08-03
US202063121837P 2020-12-04 2020-12-04
US63/121,837 2020-12-04
US202163173180P 2021-04-09 2021-04-09
US63/173,180 2021-04-09
PCT/US2021/044240 WO2022031630A1 (en) 2020-08-03 2021-08-02 Classifying tumors and predicting responsiveness

Publications (1)

Publication Number Publication Date
CN116322639A true CN116322639A (zh) 2023-06-23

Family

ID=80118483

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180066703.2A Pending CN116322639A (zh) 2020-08-03 2021-08-02 肿瘤分类和反应性预测

Country Status (8)

Country Link
US (1) US20230296584A1 (enExample)
EP (1) EP4188330A4 (enExample)
JP (1) JP2023536636A (enExample)
KR (1) KR20230058410A (enExample)
CN (1) CN116322639A (enExample)
AU (1) AU2021322092A1 (enExample)
CA (1) CA3188358A1 (enExample)
WO (1) WO2022031630A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121737300A (zh) * 2025-12-18 2026-03-27 湖南师范大学 用于无创检测口腔癌的联用肿瘤标志物及其应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114835640B (zh) * 2022-05-24 2024-02-13 中国药科大学 成纤维细胞生长因子受体抑制剂、制备方法及应用
CN115436636A (zh) * 2022-11-08 2022-12-06 济南市中心医院 连接粘附分子样蛋白jaml在结直肠癌中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150354009A1 (en) * 2012-11-26 2015-12-10 Ecole Polytechnique Federale De Lausanne (Epfl) Colorectal cancer classification with differential prognosis and personalized therapeutic responses
CN108138236A (zh) * 2015-07-21 2018-06-08 阿尔麦克诊断有限公司 用于癌症中免疫治疗的基因标签
US20180216197A1 (en) * 2017-01-20 2018-08-02 Genomedx Biosciences, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
US20190184031A1 (en) * 2017-12-19 2019-06-20 Abraxis Bioscience, Llc Methods of treating colon cancer using nanoparticle mtor inhibitor combination therapy
CN110927389A (zh) * 2019-11-29 2020-03-27 中国科学院苏州生物医学工程技术研究所 一种癌症生物标志物、用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9517229B2 (en) * 2011-07-29 2016-12-13 Medivation Prostate Therapeutics, Inc. Treatment of breast cancer
US20210396739A1 (en) * 2018-05-01 2021-12-23 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150354009A1 (en) * 2012-11-26 2015-12-10 Ecole Polytechnique Federale De Lausanne (Epfl) Colorectal cancer classification with differential prognosis and personalized therapeutic responses
CN108138236A (zh) * 2015-07-21 2018-06-08 阿尔麦克诊断有限公司 用于癌症中免疫治疗的基因标签
US20180216197A1 (en) * 2017-01-20 2018-08-02 Genomedx Biosciences, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
US20190184031A1 (en) * 2017-12-19 2019-06-20 Abraxis Bioscience, Llc Methods of treating colon cancer using nanoparticle mtor inhibitor combination therapy
CN110927389A (zh) * 2019-11-29 2020-03-27 中国科学院苏州生物医学工程技术研究所 一种癌症生物标志物、用途

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121737300A (zh) * 2025-12-18 2026-03-27 湖南师范大学 用于无创检测口腔癌的联用肿瘤标志物及其应用

Also Published As

Publication number Publication date
US20230296584A1 (en) 2023-09-21
CA3188358A1 (en) 2022-02-10
KR20230058410A (ko) 2023-05-03
EP4188330A4 (en) 2024-09-04
JP2023536636A (ja) 2023-08-28
WO2022031630A1 (en) 2022-02-10
AU2021322092A1 (en) 2023-03-02
EP4188330A1 (en) 2023-06-07

Similar Documents

Publication Publication Date Title
JP7401710B2 (ja) 正規化バイオマーカースコアからがん治療を特定するためのシステム及び方法
Sengupta et al. Mesenchymal and adrenergic cell lineage states in neuroblastoma possess distinct immunogenic phenotypes
CN114556480A (zh) 肿瘤微环境的分类
JP2018505658A (ja) Ｐｄ−１アンタゴニストに対する応答の遺伝子シグネチャーバイオマーカーを得るための系および方法
WO2014022826A2 (en) Biomarker associated with risk of melanoma reoccurrence
CN111164103A (zh) 检测和治疗对免疫疗法应答的肝细胞癌类别的方法
US20230295736A1 (en) Compositions and methods comprising digital signatures to predict response and resistance to targeted therapy and immunotherapy
US20230296584A1 (en) Classifying tumors and predicting responsiveness
JP2024511166A (ja) 癌の標的療法
US20230290440A1 (en) Urothelial tumor microenvironment (tme) types
JP7772700B2 (ja) 神経膠芽腫を処置するための方法
US20240084391A1 (en) Diagnostic Methods and Methods of Treatment of Ovarian Cancer
US20260038698A1 (en) Pan-cancer tumor microenvironment classification based on immune escape mechanisms and immune infiltration
EP4692374A2 (en) Tumor microenvironment types in breast cancer
AU2023216680A1 (en) Classifying tumors and predicting responsiveness
JP2025076406A (ja) がん免疫療法に対する応答を予測するための方法、システム及び組成物
HK40095165A (en) Classifying tumors and predicting responsiveness
WO2021007503A1 (en) Targeting galectin-9 as a therapeutic strategy for t-cell exhaustion in t-cell acute lymphoblastic leukemia
WO2026099807A1 (en) Type-i interferon response and exhaustion gene signature as a biomarker for cancer immunotherapy
CN117321225A (zh) 癌症的靶向疗法
HK40102168A (en) Diagnostic methods and methods of treatment of ovarian cancer
Shi et al. Tumor‐Derived LAMB3 Drives Immunosuppressive LRRC15+ Fibroblast Formation During Pancreatic Ductal Adenocarcinoma Development
Jørgensen et al. E‐POSTERS
WO2024227553A1 (en) Biomarkers for use in cancer treatment and predicting responsiveness to a cancer therapy
CN120138146A (zh) 用于预测免疫检查点抑制剂治疗疗效的标志物组合及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40095165

Country of ref document: HK